Prexa Pharmaceuticals
Latest round
- Series B
Last raised
- Apr 2011
Total raised
- $6.4M
Investors
- 2
About Prexa Pharmaceuticals
Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease.
Who invested in Prexa Pharmaceuticals
2 investors across 2 rounds
See all investors in Prexa Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Prexa Pharmaceuticals
Who invested in Prexa Pharmaceuticals?
Prexa Pharmaceuticals has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Prexa Pharmaceuticals raised?
Prexa Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Prexa Pharmaceuticals last raise money?
Prexa Pharmaceuticals's most recent round on record is a Series B, in Apr 2011.
What does Prexa Pharmaceuticals do?
Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter.
Where is Prexa Pharmaceuticals headquartered?
Prexa Pharmaceuticals is headquartered in Boston, US.
Which VCs invest in companies like Prexa Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Prexa Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Prexa Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.